BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 16636082)

  • 21. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
    Adam HJ; Schurek KN; Nichol KA; Hoban CJ; Baudry TJ; Laing NM; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Jan; 51(1):198-207. PubMed ID: 17088485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial resistance of nasopharyngeal pneumococci from children from day-care centres and orphanages in Russia: results of a unique prospective multicentre study.
    Stratchounski LS; Kozlov RS; Appelbaum PC; Kretchikova OI; Kosowska-Shick K
    Clin Microbiol Infect; 2006 Sep; 12(9):853-66. PubMed ID: 16882290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial activity of DW286 against Streptococcus pneumoniae.
    Park HS; Jung SJ; Choi DR; Kwak JH
    Int J Antimicrob Agents; 2010 Sep; 36(3):230-3. PubMed ID: 20627463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
    Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
    Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
    Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
    J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Yokota S; Ohkoshi Y; Fujii N
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):76-80. PubMed ID: 19679241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
    East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005.
    Thornsberry C; Brown NP; Draghi DC; Evangelista AT; Yee YC; Sahm DF
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):32-8. PubMed ID: 18931469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
    De Vecchi E; Nicola L; Ossola F; Drago L
    J Antimicrob Chemother; 2009 Apr; 63(4):721-7. PubMed ID: 19218275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates.
    Oncü S; Punar M; Eraksoy H
    Chemotherapy; 2004 Jun; 50(2):98-100. PubMed ID: 15211085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.